Used in the treatment of advanced solid tumors, particularly in patients with MET exon 14 skipping mutations. It acts as a selective inhibitor of the MET receptor tyrosine kinase, helping to block tumor growth and spread. Currently under clinical investigation for its efficacy in non-small cell lung cancer and other MET-driven cancers. Shows promise due to high potency and ability to cross the blood-brain barrier, potentially addressing central nervous system metastases.